“We may need to rethink the guidelines,” she suggested, “especially for patients younger than 65.
“To come up with recommendations we also need to assess the risk/benefit ratio,” she continued.
“Diabetes is a high-risk group for cardiovascular events, and Japanese patients are a high-risk group for the use of aspirin because of their risk of hemorrhagic stroke. Conducting this study in Japan, therefore, makes sense. … The safety [in JPAD] was quite reasonable for low-dose aspirin,” she said.